Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas

Abstract

BACKGROUND AND AIM: (18)F-Fluoro-2-deoxy-d-glucose positron emission tomography ((18)FDG-PET) is promising for diagnosis and treatment of various malignancies. The aim of this study was to evaluate the clinical usefulness of (18)FDG-PET in differential diagnosis and staging of cholangiocarcinomas according to the intrahepatic, perihilar and common bile duct lesions and to compare with computerized tomography (CT) scan.

METHODS: From January 2000 to September 2003, 54 patients with suspected cholangiocarcinoma underwent abdominal CT scan and (18)FDG-PET within a 2-week period. The PET images were analyzed visually and semiquantitatively.

RESULTS: The overall accuracy of (18)FDG-PET for discriminating malignant diseases of bile duct from benign conditions was slightly higher than that of CT scan (88.9% vs 81.5%). The sensitivity of (18)FDG-PET in perihilar cholangiocarcinoma was lower than the value of intrahepatic and common bile duct cancers (83.3% vs 91.3%, 90.9%); moreover, in cases of perihilar cancer, the sensitivity of (18)FDG-PET was lower than that of CT scans (83.3% vs 91.7%). (18)FDG-PET detected nine distant metastatic lesions not found by other imaging studies and excluded two patients who potentially had resectable condition in other imaging studies from unnecessary laparotomy.

CONCLUSION: The clinical usefulness of (18)FDG-PET in differential diagnosis of bile duct cancers is related to the site of primary disease. Although it is a helpful method for differential diagnosis especially in cases of intrahepatic and common bile duct cancers, (18)FDG-PET can not provide confirmative clues in perihilar cholangiocarcinoma. (18)FDG-PET may hold promise in the detection of hidden distant metastasis and can play an additional role in the evaluation of resectability. (18)FDG-PET can be complementary to CT scan in diagnosing and staging of cholangiocarcinoma